J Korean Soc Echocardiogr.  1994 Dec;2(2):187-191. 10.4250/jkse.1994.2.2.187.

LV Mass and Left Ventricular Systolic Function After Antihypertensive Theraphy

• Cheong ER
• Chae SC
• Jun JE
• Park WH

• KMID: 2410447
• DOI: http://doi.org/10.4250/jkse.1994.2.2.187

Abstract

BACKGROUND
Left ventricular hypertrophy is one of independent predictors of cardiovascular mortality and morbidity. Many studies have shown that the left ventricular hypertrophy could be regressed with the anti-hypertensive therapy. This study was designed to clarify that the left ventricular hypertrophy could be regressed with the anti-hypertensive therapy. METHOD: Thirty six patients with essential hypertension were studied and patients with coronary heart disease, valvular heart disease, or secondary hypertension were excluded. Echocardiographic measurements were obtained at the start of anti-hypertensive therapy and followed up after 6 months of therapy or later. Used anti-hypertensive agents were calcium channel blockers, Angiotensin converting enzyme inhibitors, beta blockers or diuratics, alone or combined. RESULT: The results can be summareid as follows. 1) Mean initial blood pressure was 158/100mmHg and significantly fell to 135/83 after anti-hypertensive therapy. 2) Mean LV mass was also markedly reduced from 302 grams to 255 grams. 3) Fractional shortening and ejection fraction were increased from 33% to 36% and from 68% to 73% respectively.
CONCLUSION
These results suggest that antihypertensive therapy could reduce left ventricular hypertrophy and improve left ventricular systolic function.

Keyword

Hypertension; Left ventricular hypertrophy

MeSH Terms

Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Agents
Blood Pressure
Calcium Channel Blockers
Coronary Disease
Echocardiography
Heart Valve Diseases
Humans
Hypertension
Hypertrophy, Left Ventricular
Methods
Mortality
Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Agents
Calcium Channel Blockers

Reference

References

1). Casale PN, Devereux RB, Milner M, Zullo G, Harshfield GA, Pickering TG, Laragh JH. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Int Med. 105:173–178. 1986.

2). Levy D, Garrison RJ. Left ventricular mass and incidence of coronary heart disease in elderly cohort. Ann Int Med. 110(I):101–107. 1989.

3). Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med. 322:1561–6. 1990.

4). Ghali JK, Lao Y, Brian S, Castner A, Cao G, Cooper RS. The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann Int Med. 117:831–836. 1992.

5). Kostis JB, Ralph PA, Berkson DM, Curb JD, Grimm RH. Correlates of ventricular ectopic activity in isolated systolic hypertension. Am Heart J. 127:112–21. 1994.

6). Levy D, Anderson KM, Savage DD, Balkus SA, Kannel WB, Castelli WP. Risk of ventricular arrhthmias in left ventricular hypertrophy: The Framingham heart study. Am J Cardiol. 60:560–565. 1987.

7). Hammond IW, Devereux RB, Alderman MH, Lutas EM, Spitzer MC, Crowley JS, Laragh JH. The prevalence and correlates of echocardiographic left ventricular hypertrophy among employed patients with uncomplicated hypertension. JACC. 7:639–650. 1986.

8). Phillips RA, Ardeljan M, Shimabukuros S, Goldman ME, Garbowit DL, Eison HB, Krakoff LR. Effects of Nifedipine-GITS on left ventricular mass and left ventricular filling. J cardiovasc pharmacol. 19(suppl. 2):S28–S34. 1992.

9). Frishman WH, Skolnik AE, Strom JA. Effects of calcium entry blockade on hypertension-induced left ventricular hypertrophy. Circulation. 80(suppl. IV):IV–151-IV-161. 1989.

10). Leenen FH, Holliwell DL. Antihypertensive effect of felodipine associated with persistent sympathetic activation and minimal regression of left ventricular hypertrophy. Am J Cardiol. 69:639–645. 1992.

11). Schulaman SP, Weiss JL, Becker LC, Gottlieb SO. The effects of antihypertensive therapy on left ventricular mass in elderly patients. N Engl J Med. 322:1350–1356. 1990.

12). Dunn FG, Ventura HO, Messerli FH, Koblin I, Frohlich ED. Time course of regression of left ventricular hypertrphy in hypertensive patients treated with atenolol. Circulation. 76:254–258. 1987.

13). Guller B, Hall J, Reeves RL. Cardiac effects of trandolapril in hypertension. Am Heart J. 125(15):36–41. 1993.

14). Szlachcic J, Tubau JF, Vollmer C, Massie BM. Effect of diltiazem on left ventricular mass and diastolic filling in mild to moderate hypertension. Am J Cardiol. 63:198–201. 1989.

15). 최태열 • 김재필 • 강홍선 • 조정휘 · 김권삼 • 김영 식 • 송정상 • 배종화. 고혈압 치료에 따른 화심실 질량의 퇴행에 관한 연구 순환기. 23:898. 1993.

16). 김광호 • 정상만 • 김향인 • 주용진 • 이영수 • 김기 영 • 문언수 • 정시전. 본태성 고혈압 환자에서 강. 22:831–837. 1992.

17). Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography. Circulation. 58:1072–1083. 1978.

18). Levy D, Savage DD, Garrison RJ, Anderson KM, Kannel WB, Castelli WP. Echocardiographic criteria for left ventricular hypertrophy: The Framingham heart study. Am J Cardiol. 59:956–960. 1987.

19). Frohlich ED, Apstein C, Chobanian AV, Devereux RB, Dustan HP. The heart in hypertenson. N Engl J Med. 327:998–1008. 1992.

20). Morgan HE, Barker KM. Cardiac hypertrophy, mechanical, neural, endocrine dependence. Circulation. 83:13–25. 1991.

21). Liebson PR, Grandits G. Echocardiographic correlates of left ventricular structure among 844 midly hypertensive men and women in the treatment of mild hypertension stydy. Circulation. 87:476–486. 1993.

22). 신 순 · 강정채 • 박옥규. 본태성 고혈압환자의 좌 심실비대의 평가방법으로서의 심전도, 흉부방사선 및 심초음파도의 비교 대한내과잡지. 36:55–64. 1989.